Xenetic Biosciences Inc (XBIO) gains 8.52% for July 21

Equities Staff  |

Xenetic Biosciences Inc (NASDAQ: XBIO) shares gained 8.52%, or $0.15 per share, to close Wednesday at $1.91. After opening the day at $1.76, shares of Xenetic Bio fluctuated between $1.96 and $1.76. 322,928 shares traded hands a decrease from their 30 day average of 944,867. Wednesday's activity brought Xenetic Bio’s market cap to $16,706,182.

Xenetic Bio is headquartered in Framingham, Massachusetts..

About Xenetic Biosciences Inc

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on progressing XCART™, a personalized CAR T platform technology engineered to target patient- and tumor-specific neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient's malignant tumor cells for the treatment of B-cell lymphomas. XCART™ has the potential to fuel a robust pipeline of therapeutic assets targeting high-value oncology indications.

Visit Xenetic Biosciences Inc’s profile for more information.

About The Nasdaq Stock Market

The Nasdaq Stock Market is a global leader in trading data and services, and equities and options listing. Nasdaq is the world's leading exchange for options volume and is home to the five largest US companies - Apple, Microsoft, Amazon, Alphabet and Facebook.

To get more information on Xenetic Biosciences Inc and to follow the company’s latest updates, you can visit the company’s profile page here: Xenetic Biosciences Inc’s Profile. For more news on the financial markets be sure to visit Equities News. Also, don’t forget to sign-up for the Daily Fix to receive the best stories to your inbox 5 days a week.

Sources: Chart is provided by TradingView based on 15-minute-delayed prices. All other data is provided by IEX Cloud as of 8:05 pm ET on the day of publication.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer

Market Movers

Sponsored Financial Content